Liquid biopsy: current technology and clinical applications
M Nikanjam, S Kato, R Kurzrock - Journal of hematology & oncology, 2022 - Springer
Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision
oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA) …
oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA) …
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer
METHODS This guideline is based on the previous colon cancer parameter published in
2017. 10 Compared with 2017, this guideline has 11 new, 10 updated, and 2 excluded …
2017. 10 Compared with 2017, this guideline has 11 new, 10 updated, and 2 excluded …
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
Circulating tumor DNA and liquid biopsy in oncology
Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
Current and future perspectives of liquid biopsies in genomics-driven oncology
Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …
Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges
Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications
in cancer management. While its role in guiding precision medicine in certain tumors via …
in cancer management. While its role in guiding precision medicine in certain tumors via …
Trends in the approval of cancer therapies by the FDA in the twenty-first century
EC Scott, AC Baines, Y Gong, R Moore Jr… - Nature Reviews Drug …, 2023 - nature.com
The cancer treatment landscape has changed dramatically since the turn of the century,
resulting in substantial improvements in outcomes for patients. This Review summarizes …
resulting in substantial improvements in outcomes for patients. This Review summarizes …
Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer
T Reinert, TV Henriksen, E Christensen… - JAMA …, 2019 - jamanetwork.com
Importance Novel sensitive methods for detection and monitoring of residual disease can
improve postoperative risk stratification with implications for patient selection for adjuvant …
improve postoperative risk stratification with implications for patient selection for adjuvant …